Fusion Antibodies Plc
Fusion Antibodies is a highly specialised CRO (contract research organisation) operating in the[CM1] field of monoclonal antibody (mAb) production and engineering. The global CRO market is estimated to be worth over $30bn growing at a CAGR of c 12% pa to 2020. The Company is well established and differentiated by means of its expertise, technology and the quality of its partnerships. The existing customer base includes top five ‘big pharma’, and is globally spread. Fusion has a proven record of revenue growth (up by 220% from FY15-17) with a FY17 reported EBITDA margin of 8%. The Company is entering a period of expansion targeting geographic growth and investing in greater capacity to meet sustained demand for its services.
|23 January 2018